Posted by Michael Wonder on 10 Oct 2023
AbbVie’s Aquipta (atogepant) is now available in Scotland for the prevention of migraines in adults
9 October 2023 - The SMC has accepted Aquipta (atogepant), the oral, once daily calcitonin gene-related peptide receptor antagonist for restricted use within NHS Scotland.
AbbVie today announced that the SMC has accepted Aquipta (atogepant) for restricted use within NHS Scotland for the prophylaxis of migraine in adults who have at least four migraine days per month and for patients with chronic and episodic migraine who have had prior treatment failure on three or more migraine preventive treatments.
